Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3

Executive Chairman and CEO Bob Proulx said, “we ended the year on an upbeat note having had strong shareholder support in the exercise of options and four sites actively recruiting for the MagSense® HER2 breast cancer study with multiple patients having completed the study. We now start 2022 having moved into a new facility that greatly expands our R&D capabilities and adds manufacturing capacity to support the commercial development of our nanoparticle products. Adding, “We feel the study is progressing in a positive direction and will provide material updates as they arise.”